RxDoctor Payments Data

Brenda Mullins, MD

Interventional Cardiology · Oklahoma City, OKNPI 1235133778

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $4,607 of the $7,639 with a category attached, or 60.3%. 19 manufacturers reported payments, led by Medtronic at 59.7% of the total. Reporting peaked in 2022 at $4,493 and has fallen 95.9% since, to $183 in 2025. That places this record below the midpoint for interventional cardiology clinicians in OK, where the typical reported total is $7,360.

$7,639in general payments, 2019–2025

Across 171 payments — averaging $44.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$5K
  • Abbott$1K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$518
  • AstraZeneca$253
  • Novartis$218
  • Amgen$143
  • plus $688 from 13 others

What the payments were for

  • Travel & lodging$3,03240%
  • Food & beverage$4,60760%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,639 in reported general payments places this provider in the 50th percentile of 110 interventional cardiology providers in Oklahoma.

See all interventional cardiology providers in Oklahoma

Medicare billing

Part B allowed, 2024
$82,137
Medicare patients
612
Services billed
1,104

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban212$180,794
EntrestoSacubitril/Valsartan29$37,406
XareltoRivaroxaban39$30,871
BrilintaTicagrelor35$18,799
Repatha SureclickEvolocumab13$9,785
Metoprolol Succinate391$4,545
Atorvastatin Calcium113$1,486
Losartan Potassium165$1,201
Potassium Chloride97$1,075
ClopidogrelClopidogrel Bisulfate110$919
Carvedilol156$862
Lisinopril120$714
Amlodipine Besylate80$714
Metoprolol Tartrate115$592
Rosuvastatin Calcium18$539

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$38$180,794212 claims
NovartisEntresto$218$37,40629 claims
Johnson & JohnsonXarelto$88$30,87139 claims
AstraZenecaBrilinta$253$18,79935 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 110 interventional cardiology providers in Oklahoma.

Other interventional cardiology in Oklahoma City

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →